

Date and Time: Friday 30th November 2012, 10:00 – 16:30

Minutes:

Lipid Modification Guideline

Guideline Development Group Meeting 3

Place: Boardroom, National Clinical Guideline Centre, Royal College of Physicians, 180 Great Portland Street, London W1W 5QZ

GDG Present:	Anthony Wierzbicki (Chair)	(Present for notes 1 – 7)
	Rajai Ahmad	(Present for notes 1 – 7)
	Lindsay Banks	(Present for notes 1 – 7)
	Liz Clark	(Present for notes 1 – 7)
	Martin Duerden	(Present for notes 1 – 7)
	Eleanor Grey	(Present for notes 1 – 7)
	Emma McGowan	(Present for notes 1 – 7)
	Dermot Neely	(Present for notes 1 – 7)
	Nadeem Quershhi	(Present for notes 1 – 7)
	Alan Rees	(Present for notes 1 – 7)
	David Wald	(Present for notes 1 – 7)
NCGC Present:	Angela Cooper	(Present for notes 1 – 7)
	Martin Harker	(Present for notes 1 – 7)
	Norma O’Flynn	(Present for notes 1 – 7)
	Silvia Rabar	(Present for notes 1 – 7)
	Lina Gulhane	(Present for notes 1 – 7)

In attendance:

NICE Staff:	Clifford Middleton	
-------------	--------------------	--

Observers:

--	--	--

Agenda item

1. Welcome introductions and apologies

Anthony Wierzbicki welcomed the group to the third meeting of this GDG and thanked them for their time and commitment to the guideline. Apologies were received from Michael Khan, David Wonderling, and Alison Richards.

2. Declaration of Interests

The Chair asked all GDG members to declare any new relevant conflicts of interest. The group then verbally declared the following new DOIs:

<p>Alan Rees. Personal pecuniary interest: Recently chaired a medical meeting on diabetes, sponsored by AZ Pharmaceuticals.</p>

3. Statins review strategy. Agree protocols for: efficacy, adverse events, adherence

Agenda item

The Chair gave a presentation on the background of statins recommendations and possible approaches for the review. The GDG discussed the different options and implications of the different options and agreed the protocols.

4. **Review question: For adults with and without CVD, what is the clinical and cost effectiveness of fibrates versus placebo in preventing cardio-vascular disease?**

The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the clinical and cost effectiveness of fibrates in secondary prevention of cardio-vascular disease and in people with diabetes, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline and developed draft recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.

5. **Review question: For adults with and without CVD what is the clinical and cost effectiveness of omega 3 fatty acids versus placebo in preventing cardio-vascular disease?**

There was not enough time to discuss this agenda item, and it is carried forward for the next meeting.

6. **Health economics plan**

There was not enough time to discuss this agenda item, and it is carried forward for the next meeting.

7. **Summary of next steps and any other business**

There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

Wednesday 6th February 2013, 10.00 – 16.00, at Royal College of Physicians, Henry Cohen Room.